EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Post-marketing safety evaluation of anthracycline for acute myeloid leukemia treatment: a real-world pharmacovigilance analysis

Yong Wang, Qian Liu, Jing Xu, Fei Yang, Meiyan Wang, Haoxiang Lu, Jie Wu, Ao Zhang, Xingli Zhang, Dehong Wu, Hongchun Qiu

Frontiers in Pharmacology · 10.06.2026 · 17

DOI: 10.3389/fphar.2026.1759201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.06.2026. Verfasst von Yong Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Kunshan Third People's Hospital, Suzhou, China. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anthracyclines are key for acute myeloid leukemia (AML) but carry serious side effects. This study identifies their side effects across drugs and patient populations using the FDA Adverse Event Reporting System (FAERS). Materials and methods We analyzed 1,079 AML cases and 3,622 adverse events (AEs) from FAERS (2004–2024). Disproportionality analyses (PRR, ROR, BCPNN, MGPS) detected AE signals; Kruskal–Wallis tests evaluated time-to-onset by age/sex.

Results

Distinct risks emerged: epirubicin (strongest cardiotoxicity, ROR = 10.57), doxorubicin (highest pregnancy-related AEs, ROR = 9.97), daunorubicin (vascular disorders, ROR = 2.38), idarubicin (myelosuppression/infections). Most AEs occurred within 180 days. Idarubicin showed delayed onset in elderly (P < 0.05); males had delayed doxorubicin toxicity (P = 0.04) but accelerated idarubicin onset (P = 0.049) vs. females.

Conclusion

This analysis identifies distinct safety profiles. Epirubicin and doxorubicin were associated with cardiac and pregnancy-related risks, while idarubicin showed signals suggesting potentially delayed onset in elderly patients. Observed sex differences indicate possible variations in AE patterns.

Schlagwörter

Stichwörter der Autor:innen

FAERSacute myeloid leukemiaanthracyclinesdrug safetypharmacovigilance

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Kunshan Third People's Hospital, Suzhou, China.

Zitieren

APA

Wang, Y., Liu, Q., Xu, J., Yang, F., Wang, M., Lu, H., Wu, J., Zhang, A., Zhang, X., Wu, D., & Qiu, H. (2026). Post-marketing safety evaluation of anthracycline for acute myeloid leukemia treatment: a real-world pharmacovigilance analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1759201

Vancouver

Wang Y, Liu Q, Xu J, Yang F, Wang M, Lu H, et al. Post-marketing safety evaluation of anthracycline for acute myeloid leukemia treatment: a real-world pharmacovigilance analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1759201

BibTeX
@article{Wang2026,
  author = {Wang, Yong and Liu, Qian and Xu, Jing and Yang, Fei and Wang, Meiyan and Lu, Haoxiang and Wu, Jie and Zhang, Ao and Zhang, Xingli and Wu, Dehong and Qiu, Hongchun},
  title = {Post-marketing safety evaluation of anthracycline for acute myeloid leukemia treatment: a real-world pharmacovigilance analysis},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1759201}
}
Kostenlos starten →